Moreover, the founding member of this family, zyxin has recently been identified as a potential biomarker for the aggressive phenotypes of human brain cancer (glioblastoma multiforme), exhibits differential expression levels in melanocytes/melanoma cells and altered phosphorylation in colon cancer, and is found to be associated with poor prognosis in glioma patients [10]. Here, ZYX is linked to melanoma.